-
2022-501562-22-00
4
Triple-negative breast cancer (TNBC) patients at high risk of relapse
-
2023-508062-15-00
5
Primary Hyperoxaluria (PH) of all subtypes (PH1, PH2 and PH3)
-
2023-508664-30-00
5
Acute kidney injury
-
2024-510811-32-00
5
acute pneumonia
-
2024-516052-17-01
10
Patients with a diagnosis of IgAV according to Chapel Hill Consensus C
-
2024-516182-37-01
4
Maintenance treatment in patients with locally advanced/metastatic uro
-
2024-517621-54-00
5
High-risk non-muscle invasive bladder cancer (NMIBC) after transurethr
-
2024-518139-12-00
4
locally advanced or metastatic Pancreatic ductal adenocarcinoma
-
2024-518437-28-00
5
Sickle cell disease
-
2024-518554-17-00
4
type 1 diabetes mellitus
-
2025-521619-37-00
5
Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to r
-
2025-521908-22-00
10
EGFR-mutated Non-small Cell Lung Cancer
-
2025-522996-27-00
5
2026-05-05
recurrent and/or metastatic squamous cell carcinoma of the head and ne
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2024-514799-42-00
4
2024-11-05
IDIOPATHIC PULMONARY FIBROSIS
-
2023-504308-27-00
5
2024-06-06
non-squamous non-small cell lung cancer
-
2023-504670-38-00
4
2023-11-17
Extensive disease Small Cell Lung Cancer
-
2022-501007-28-00
5
2023-04-18
Breast Neoplasms
-
2023-505749-14-00
5
2022-03-20
c-Met overexpressing EGFR wildtype non-squamous non-small cell lung ca
-
2023-509628-16-00
5
2026-05-07
Small Cell Lung Cancer (SCLC)
-
2024-515658-26-00
5
2026-01-21
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-
-
2022-501562-22-01
4
2026-01-05
Triple-negative breast cancer (TNBC) patients at high risk of relapse
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2024-519971-25-00
5
2025-12-03
Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer